AC102 restores hearing in a preclinical model of sudden hearing loss by protecting inner ear neurons and their neuronal connections
A Phase-2-clinical study evaluates the efficacy of AC102 in sudden hearing loss patients

A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models. This is the key finding of a recent publication in the prestigious scientific journal PNAS by the Berlin-based start-up AudioCure Pharma. Sudden hearing loss is often treated with anti-inflammatory corticosteroids without regulatory approval or reliable evidence of effectiveness. Therefore, new treatment options are urgently needed for this condition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327023592/en/

Inner hair cells in the inner ear (picture: Nemes Laszlo/Shutterstock.com)

Noise-induced hearing loss was used to evaluate the efficacy of AC102 in a preclinical model. A single middle ear application of AC102 after noise trauma restores hearing to near pre-trauma levels after 14 days. In contrast, treatment without the active compound resulted in a profound hearing loss. Further experiments show that AC102 targets the two suspected main causes of sudden hearing loss in the inner ear: It prevents the death of outer hair sensory cells and protects the connections between neurons and the auditory nerve. “It is fascinating how a single molecule has such diverse effects in the inner ear. In laboratory experiments, we see that AC102 protects neurons by increasing their energy production and reducing the production of free radicals. At the same time, it stimulates the regeneration of neurons and sensory cells enabling the reformation of lost connections,” explains Professor Hans Rommelspacher, CSO and founder of AudioCure Pharma.

Sudden hearing loss is a debilitating condition that can severely impair speech understanding and have a negative impact on a patient's life. Corticosteroids have been used to treat this condition for 50 years, despite lack of approval. Also, their effectiveness has been questioned. Recently, a large study (HODOKORT) showed that more than 60% of patients with sudden hearing loss did not fully recover after corticosteroid treatment. Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma, explains, "The HODOKORT study highlights the treatment gap for sudden hearing loss. We are therefore very excited about the promising effects of AC102 in our preclinical models and hope that patients will also benefit from it." Following successful safety and tolerability testing, AC102 is currently being evaluated for efficacy in a pan-European Phase 2 clinical study in patients with sudden hearing loss.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327023592/en/

AudioCure Pharma GmbH
Frauke Luers
Phone: +49 30 2218 397-0
E-Mail: pr@ac-clinical.com
Web: www.audiocure.com

Logo

Images

Tags

More Like This

Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study

AudioCure Pharma Receives Hearing Technology Innovator Award for its Innovative Compound AC102 for the Treatment of Sudden Hearing Loss

InfectoPharm Invests in AudioCure to Advance Innovative Hearing Loss Therapy

Sudden Hearing Loss: Recent Clinical Trial HODOKORT Questions Benefits of Glucocorticoid Treatment

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

ACOUSIA THERAPEUTICS REACHES 50% PATIENT ENROLLMENT MILESTONE IN PHASE 2 PROHEAR STUDY

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Real World Data Supports Lenire Tinnitus Treatment Effectiveness Shown in Large-Scale Clinical Trials